Antiviral Effect, Safety, and Tolerability of Oral VH4011499, a New Human Immunodeficiency Virus Capsid Inhibitor: Proof-of-Concept Trial
Clinical Infectious Diseases·
- DOI
- 10.1093/cid/ciag452
- PMID
- 42525562
- PMCID
- —
- OpenAlex
- W7171710265
- Study type
- Journal article
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The abstract identifies a need for innovative HIV-1 therapies, particularly those permitting infrequent dosing, and states that these results support further development of VH4011499 as a component of a complete long-acting treatment regimen.
Structured evidence summary
Research question
The trial evaluated the antiviral effect, pharmacokinetics, safety, and tolerability of oral VH4011499 monotherapy in adults with HIV-1 who were naive to antiretroviral therapy.
Study design
This was a randomized, double-blind, placebo-controlled phase 2a proof-of-concept trial with a 10-day monotherapy period, followed by initiation of standard-of-care antiretroviral therapy on Day 11.
Population and setting
Twenty-three adults with HIV-1 viremia who were naive to antiretroviral therapy were enrolled; 20 received VH4011499 and 3 received placebo.
Main findings
Viral load declined through Day 11 at all tested VH4011499 doses, with mean maximum declines ranging from 1.8 to 2.2 log10 units; higher exposures were associated with greater declines. Nineteen of 20 VH4011499 participants had no emergent genotypic resistance-associated mutations, and all reported adverse events were mild or moderate, with no serious adverse events or withdrawals due to adverse events.
Public-health relevance
The abstract identifies a need for innovative HIV-1 therapies, particularly those permitting infrequent dosing, and states that these results support further development of VH4011499 as a component of a complete long-acting treatment regimen.
Important limitations
This proof-of-concept study was small, had only 3 placebo recipients, and assessed short-term VH4011499 monotherapy in ART-naive adults. It does not establish long-term efficacy, safety, resistance durability, clinical outcomes, or effectiveness in a complete antiretroviral regimen.
GIDS interpretation
The article is discoverable within GIDS through its disease classification of AIDS and treatment/transmission-dynamics topic tags. This classification provides research context only and does not connect the trial findings to a current surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.